XML 49 R37.htm IDEA: XBRL DOCUMENT
v3.21.2

Revenue - Additional Information (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended
--- | --- | --- | ---
Jun. 30, 2021 | Jun. 30, 2020 | Jun. 30, 2021 | Jun. 30, 2020 | Dec. 31, 2020 | Dec. 31, 2019
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |
Revenue | $ 2,218 | $ 13,384 | $ 6,576 | $ 20,462 |  |
Accounts receivable | 2,919 |  | 2,919 |  | $ 1,822 |
Collaboration Revenue [Member] |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |
Revenue | 2,218 | 13,384 | 3,576 | 20,462 |  |
Neurocrine Biosciences [Member] |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |
Accounts receivable | 1,624 |  | 1,624 |  |  |
Deferred revenue | 3,025 |  | 3,025 |  |  |
Flexion [Member] | Collaboration Revenue [Member] |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |
Milestone payments |  |  | 3,000 |  |  |
Exclusive License to XEN901 and Exclusive License to DTCs [Member] | Neurocrine Biosciences [Member] | Collaboration Revenue [Member] |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |
Revenue |  | 11,523 |  | 17,285 |  |
Development Services Under the Initial Development Program For DTCs [Member] | Neurocrine Biosciences [Member] | Collaboration Revenue [Member] |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |
Revenue | 617 | 393 | 617 | 475 |  |
Research And Development Funding | Neurocrine Biosciences [Member] | Collaboration Revenue [Member] |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |
Revenue | 1,601 | $ 1,468 | 2,959 | $ 2,702 |  |
License and Collaboration Agreement [Member] | Neurocrine Biosciences [Member] |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |
Upfront payment received in cash |  |  |  |  |  | $ 30,000
Upfront payment received in equity investment |  |  |  |  |  | 20,000
Equity investment measured at fair value |  |  |  |  |  | 16,667
Collaborate agreement premium related to equity investment |  |  |  |  |  | 3,333
Transaction price allocated to performance obligations |  |  |  |  |  | 33,333
Variable consideration allocated to performance obligation |  |  | $ 592 |  |  |
Percentage of option to co-fund development costs upon achievement of certain milestones |  |  | 50.00% |  |  |
License and Collaboration Agreement [Member] | Exclusive License to XEN901 and Exclusive License to DTCs [Member] | Neurocrine Biosciences [Member] |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |
Transaction price allocated to performance obligations |  |  |  |  |  | $ 28,807
License and Collaboration Agreement [Member] | Development Services Under the Initial Development Program For DTCs [Member] | Neurocrine Biosciences [Member] |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |
Transaction price allocated to performance obligations |  |  |  |  | $ 5,118 |
Asset Purchase Agreement [Member] | Flexion [Member] |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |
Milestone payment due on initiation of Phase 1b clinical trial |  |  | $ 2,000 |  |  |
Asset Purchase Agreement [Member] | Flexion [Member] | XEN402 [Member] |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |
Milestone payments |  |  | 1,000 |  |  |
Asset Purchase Agreement [Member] | Eligible to Receive Development Milestone Payment [Member] | Flexion [Member] | XEN402 [Member] | Maximum [Member] |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |
Potential milestone payments receivable | 5,000 |  | 5,000 |  |  |
Asset Purchase Agreement [Member] | Future Clinical Development And Global Regulatory Approval Milestone Payments [Member] | Flexion [Member] | XEN402 [Member] | Maximum [Member] |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |
Potential milestone payments receivable | 40,750 |  | 40,750 |  |  |
Asset Purchase Agreement [Member] | Commercial Milestone Payments [Member] | Flexion [Member] | XEN402 [Member] | Maximum [Member] |  |  |  |  |  |
Disaggregation Of Revenue [Line Items] |  |  |  |  |  |
Potential milestone payments receivable | $ 75,000 |  | $ 75,000 |  |  |

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 45 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Aggregate price of transaction allocated to performance obligations + References No definition available. + Details
Name: | xene_AggregatePriceOfTransactionAllocatedToPerformanceObligations
Namespace Prefix: | xene_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaborate agreement premium related to equity investment. + References No definition available. + Details
Name: | xene_CollaborateAgreementPremiumRelatedToEquityInvestment
Namespace Prefix: | xene_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payment. + References No definition available. + Details
Name: | xene_MilestonePayment
Namespace Prefix: | xene_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payment due on initiation of Phase 1b clinical trial. + References No definition available. + Details
Name: | xene_MilestonePaymentDueOnInitiationOfPhase1bClinicalTrial
Namespace Prefix: | xene_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of option to fund development costs upon achievement of certain milestones. + References No definition available. + Details
Name: | xene_PercentageOfOptionToFundDevelopmentCostsUponAchievementOfCertainMilestones
Namespace Prefix: | xene_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential milestone payments receivable. + References No definition available. + Details
Name: | xene_PotentialMilestonePaymentsReceivable
Namespace Prefix: | xene_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Upfront payment in cash. + References No definition available. + Details
Name: | xene_UpfrontPaymentInCash
Namespace Prefix: | xene_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront payment received in equity investment. + References No definition available. + Details
Name: | xene_UpfrontPaymentReceivedInEquityInvestment
Namespace Prefix: | xene_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront payment received in equity investment measured at fair value. + References No definition available. + Details
Name: | xene_UpfrontPaymentReceivedInEquityInvestmentMeasuredAtFairValue
Namespace Prefix: | xene_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Variable consideration allocated to performance obligation. + References No definition available. + Details
Name: | xene_VariableConsiderationAllocatedToPerformanceObligation
Namespace Prefix: | xene_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xene_NeurocrineBiosciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=xene_FlexionTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis=xene_ExclusiveLicenseToXEN901AndExclusiveLicenseToDTCsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis=xene_DevelopmentServicesUnderInitialDevelopmentProgramForDTCsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis=xene_ResearchAndDevelopmentFundingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xene_LicenseAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=xene_AssetPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=xene_XEN402Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis=xene_EligibleToReceiveDevelopmentMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis=xene_FutureClinicalDevelopmentAndGlobalRegulatoryApprovalMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentAssetsAcquiredOtherThanThroughBusinessCombinationByTransactionAxis=xene_CommercialMilestonePaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |